Product Information
GSK 3532795 is a new drug for the treatment of HIV-1 infection. It is currently in Phase II clinical trials, which are expected to complete by 2020. GSK 3532795 is a novel non-nucleoside reverse transcriptase inhibitor that has been shown to be active against both wild type and M184V mutant strains of HIV-1 and has potent activity in vitro against HIV-1 with reduced susceptibility to other antiretroviral drugs. This drug also inhibits the expression of CXCR4 and CCR5 co-receptors, which may play an important role in viral entry into CD4+ T cells.
Chemical properties
Technical inquiry about: 3D-SFC31245 GSK 3532795
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
